SHARC
Pre-clinical- Indications
- Organ transplant rejection, Antibody-mediated rejection
Company intelligence / Profile preview
Pure Transplant Solutions is developing novel HLA-based immunotherapeutic and diagnostic products aimed at reducing or eliminating both chronic and acute antibody-mediated rejection in organ transplantation. Their lead efforts focus on personalized diagnostics to detect donor-specific antibodies without compromising the immune system. The company has announced collaborations with academic centers and industry partners to validate its technology but has not yet reported late-stage clinical results.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Pure Transplant Solutions.